Heart failure (HF) affects 6.2 million people in the United States, with 1 million new cases occurring annually and a resultant 1 million hospitalizations, which translates into an annual estimated cost of over $30 billion dollars. Mortality with this condition is high, approximately 50% at five years. Implementation of the advances in management of heart failure have the potential to improve patients' quality of life, reduce the need for hospitalizations, reduce total medical costs, and prolong survival. This lecture will review the current evidence-based, guideline-recommended diagnosis and management of heart failure. You will learn the essential roles of evidence-based heart failure medications, device therapy, patient education, and disease management.
This talk will review data on the current diagnosis and management of acute coronary syndromes (ACS). Participants will learn about the scope of the clinical problem, the pathophysiology of ACS, and diagnostic strategies and cardiac markers as well as receive updates on clinical trials data, guideline recommendations, and management strategies. In particular, the speaker will focus on acute management and Class I recommended long-term therapies in the current guidelines that reduce the risk of recurrent events and mortality.
In this episodes, we will discuss a systematic review and meta-analysis that examines outcomes from the use of furosemide compared to torsemide in patients with congestive heart failure.
Evidence from real world studies on the effectiveness, safety, and dosing of non-vitamin-K oral anticoagulants (NOACs) provides crucial insights on the treatment of patients with atrial fibrillation (AF). In this program, you will learn to assess the quality of these studies and compare the relevance, validity, and utility of the results to those of randomized controlled trials. Judicial assessment and appropriate incorporation of real world data into clinical practice can improve the care of your patients with AF and other conditions.
Get your questions answered by expert faculty in Cardiology. You ask: we listen. You will learn practical solutions to common clinical challenges and tips to apply the latest knowledge in practice.
Adults with type 2 diabetes mellitus (T2DM) have a two- to four-fold increase in risk for cardiovascular (CV) morbidity and mortality. This session cuts to the heart of primary and secondary prevention in this population, presenting recent data on antihyperglycemic medications with proven cardiovascular benefit in the context of updated management algorithms. Individualized treatment is critical to the success of these treatment plans. The faculty will help you optimize adherence through shared decision-making tactics that account for CV risk factors, comorbidities, and patient preferences. Please note that any data, indications, and guidelines presented in this activity are current as of the recording on 6/26/2020, and they are subject to change as new information is published.
Obesity, dyslipidemia, and hypertension are significant challenges to public health and impact a growing number of Americans. Weight loss and dietary changes are effective in preventing CVD and DMII and reducing cardiometabolic complications, but can be difficult for many people. Growing evidence supports the use of timed fasting to promote weight loss and reduce these complications. Join us as we discuss a recent study that shows promising data regarding a 10-hour feeding window and improved CV markers.
Atrial fibrillation is the most common sustained cardiac arrhythmia in clinical practice and conveys a 4- to 5-fold increased risk of stroke; yet, it often goes undiagnosed and untreated in a primary care setting. In the program, Dr. Ty Gluckman discusses how to recognize patients at high risk for AF, evaluate patients newly diagnosed with AF, assess risk of bleeding and thromboembolism, and apply evidence-based recommendations to reduce thromboembolic risk. Please note that any data, indications, and guidelines presented in this activity are current as of the recording/release on 8/4/2020, and they are subject to change as new information is published.